BRANCACCIO, Giuseppina
 Distribuzione geografica
Continente #
EU - Europa 3.956
NA - Nord America 2.005
AS - Asia 1.540
SA - Sud America 428
Continente sconosciuto - Info sul continente non disponibili 142
AF - Africa 32
OC - Oceania 2
Totale 8.105
Nazione #
RU - Federazione Russa 2.574
US - Stati Uniti d'America 1.956
SG - Singapore 563
IE - Irlanda 501
BR - Brasile 351
CN - Cina 300
GB - Regno Unito 267
VN - Vietnam 233
HK - Hong Kong 230
IT - Italia 137
UA - Ucraina 128
DE - Germania 83
SE - Svezia 57
FR - Francia 56
GR - Grecia 55
KR - Corea 49
BD - Bangladesh 37
AR - Argentina 36
FI - Finlandia 32
IN - India 29
TR - Turchia 25
CA - Canada 17
CZ - Repubblica Ceca 17
JP - Giappone 17
MX - Messico 17
BE - Belgio 14
ID - Indonesia 13
AT - Austria 11
EC - Ecuador 10
IQ - Iraq 9
ZA - Sudafrica 9
PK - Pakistan 8
BO - Bolivia 6
CO - Colombia 6
ET - Etiopia 5
PE - Perù 5
PY - Paraguay 5
RO - Romania 5
CL - Cile 4
NI - Nicaragua 4
PL - Polonia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
DZ - Algeria 3
EU - Europa 3
KE - Kenya 3
MA - Marocco 3
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EG - Egitto 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
LT - Lituania 2
NL - Olanda 2
NP - Nepal 2
PH - Filippine 2
UZ - Uzbekistan 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CH - Svizzera 1
CR - Costa Rica 1
EE - Estonia 1
ES - Italia 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
HN - Honduras 1
IL - Israele 1
JO - Giordania 1
KW - Kuwait 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LY - Libia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 7.966
Città #
Moscow 968
Dublin 501
Singapore 255
Chandler 252
Santa Clara 248
Hong Kong 229
Jacksonville 199
San Jose 135
Ashburn 86
Ho Chi Minh City 83
Dallas 81
Princeton 72
Medford 69
Roxbury 65
Beijing 58
New York 56
Houston 55
Seoul 49
Hanoi 47
The Dalles 44
Munich 34
Caserta 27
Wilmington 27
São Paulo 25
Ann Arbor 22
Des Moines 22
Los Angeles 17
Brno 16
Napoli 15
Brussels 14
Da Nang 14
Nanjing 13
Milan 12
Orem 12
Haiphong 11
Atlanta 10
Bengaluru 10
Boardman 10
Bremen 10
Porto Alegre 10
Belo Horizonte 9
Nuremberg 9
Redwood City 9
Rome 9
Woodbridge 9
Campinas 8
Helsinki 8
Memphis 8
San Mateo 8
Shanghai 8
Brasília 7
Curitiba 7
Mountain View 7
Tokyo 7
Changsha 6
Frankfurt am Main 6
Nanchang 6
Ninh Bình 6
Rio de Janeiro 6
Biên Hòa 5
Cambridge 5
Chennai 5
Guadalajara 5
Guarulhos 5
Hefei 5
Philadelphia 5
Turku 5
Baghdad 4
Bagheria 4
Belford Roxo 4
Caxias do Sul 4
Clifton 4
Columbus 4
Duque de Caxias 4
Franca 4
Ha Long 4
Jakarta 4
Kyiv 4
La Paz 4
Lahore 4
Lima 4
Ribeirão Preto 4
Santo André 4
São Bernardo do Campo 4
Zhengzhou 4
Aversa 3
Bogotá 3
Buffalo 3
Camaçari 3
Can Tho 3
Chicago 3
Contagem 3
Denver 3
Fairfield 3
Fortaleza 3
Fuzhou 3
Jinan 3
Johannesburg 3
Joinville 3
London 3
Totale 4.183
Nome #
Detection of in vivo hepatitis B virus surface antigen mutations-A comparison of four routine screening assays 306
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. 180
Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections 168
3. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. 166
AISF position paper on HCV in immunocompromised patients 166
Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya, 158
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 157
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study 153
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 152
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 147
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 146
Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. 144
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 144
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 142
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 141
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 139
Virological patterns of HCV patients with failure to interferon-free regimens. 137
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 136
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 135
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 135
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis. 132
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 130
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. 128
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 127
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 126
Hepatitis delta infection in Italian patients: towards the end of the story? 126
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 126
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 125
. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience 124
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 119
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 118
An a prior prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 117
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 115
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 109
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 104
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 102
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 100
Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin 99
Interleukin-28B genetic variants in untreated Italian HCV-infected patients : a multicenter study. 98
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 97
LONG TERM SAFETY OF ANTI -TNF ALFA IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND HBV INFECTION: FOCUS ON HEPATITIS B SURFACE ANTIBODY STATUS 96
Recovery of HBV-specific T cell function in patients under long-term effective suppressive therapy by nucleos(t)ide analogues. 94
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 93
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. 92
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 92
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 91
Evolving Clinical Landscape of Chronic Hepatitis B:A Multicenter Italian Study 90
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 89
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study 89
Fever of unknown origin (FUO): Which are the factors influencing the final diagnosis? A 2005-2015 systematic review 89
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 88
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 87
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 86
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 84
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 83
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 83
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 82
Influenza vaccination in patients with cirrosi and in liver transplant recipients. 82
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 81
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 80
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 79
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 79
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 79
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 78
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 76
Platelets and hepatocellular cancer: Bridging the bench to the clinics 75
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 74
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 73
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 70
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 67
Salvage therapy with follone by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. 66
Hepatitis C Virus Clearance in Older Adults 64
Totale 8.105
Categoria #
all - tutte 29.658
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.658


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022489 0 9 12 21 174 8 12 24 25 26 36 142
2022/2023928 79 13 12 78 80 76 2 66 482 6 17 17
2023/2024305 29 8 12 8 115 50 0 7 0 6 14 56
2024/2025984 20 23 8 17 168 116 141 56 155 126 89 65
2025/20264.350 113 162 309 274 364 2.394 195 169 173 84 69 44
2026/202790 31 59 0 0 0 0 0 0 0 0 0 0
Totale 8.105